TREX1 dictates the immune fate of irradiated cancer cells

OncoImmunology

Volumn 6, Issue 9, 2017, Pages

  Vanpouille Box, Claire ^a   Formenti, Silvia C ^a   Demaria, Sandra ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

abscopal effect; cGAS; immune checkpoint blockers; nucleic acids sensing; radiotherapy; STING; type I interferon

Indexed keywords

DEOXYRIBONUCLEASE; TREX 1; UNCLASSIFIED DRUG;

BIOACCUMULATION; CANCER RADIOTHERAPY; CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE SILENCING; HUMAN; NONHUMAN; NOTE; RADIOTHERAPY DOSAGE; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; TUMOR IMMUNOGENICITY; UPREGULATION;

EID: 85028557564     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2017.1339857     Document Type: Note

References (8)

1. Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 2015; 1:1325-32; PMID:26270858; https://doi.org/10.1001/jamaoncol.2015.2756
2. Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC, Demaria S. DNA exonuclease Trex1 regulates radiotherapy-induced tumor immunogenicity. Nat Commun 2017; 8:15618 in press; https://doi.org/10.1038/ncomms15618
3. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009; 15:5379-88; PMID:19706802; https://doi.org/10.1158/1078-0432.CCR-09-0265
4. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM, Gajewski TF. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8a+ dendritic cells. J Exp Med 2011; 208:2005-16; PMID:21930765; https://doi.org/10.1084/jem.20101159
5. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011; 208:1989-2003; PMID:21930769; https://doi.org/10.1084/jem.20101158
6. Gao P, Ascano M, Wu Y, Barchet W, Gaffney BL, Zillinger T, Serganov AA, Liu Y, Jones RA, Hartmann G, et al. Cyclic [G(2′,5′)pA(3′,5′)p] is the metazoan second messenger produced by DNA-activated cyclic GMP-AMP synthase. Cell 2013; 153:1094-107; PMID:23647843; https://doi.org/10.1016/j.cell.2013.04.046
7. Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008; 134:587-98; PMID:18724932; https://doi.org/10.1016/j.cell.2008.06.032
8. Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Barber GN, Fitzgerald KA, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014; 41:830-42; PMID:25517615; https://doi.org/10.1016/j.immuni.2014.10.017